Cisplatin and its analogues in the treatment of advanced breast cancer: a review.

por Smith, I. E., Talbot, D. C.
Publicado 1992

The development of a structured rating schedule (the BAS) to assess skills in breaking bad news

por Miller, S J, Hope, T, Talbot, D C
Publicado 1999

A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours

por Wall, L, Talbot, D C, Bradbury, P, Jodrell, D I
Publicado 2004

A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia.

por Downer, S., Joel, S., Allbright, A., Plant, H., Stubbs, L., Talbot, D., Slevin, M.
Publicado 1993

Development and validation of a Brief Diet Quality Assessment Tool in the French-speaking adults from Quebec

por Lafrenière, J., Harrison, S., Laurin, D., Brisson, C., Talbot, D., Couture, P., Lemieux, S., Lamarche, B.
Publicado 2019

A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer.

por Ellis, P. A., Talbot, D. C., Nicolson, M. C., Priest, K., Ashley, S., Smith, I. E.
Publicado 1995

Phase II trial of UFT in advanced colorectal and gastric cancer.

por Malik, S. T., Talbot, D., Clarke, P. I., Osborne, R., Reznek, R., Wrigley, P. F., Slevin, M. L.
Publicado 1990

Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.

por Patterson, A. V., Zhang, H., Moghaddam, A., Bicknell, R., Talbot, D. C., Stratford, I. J., Harris, A. L.
Publicado 1995

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

por Patterson, A. V., Saunders, M. P., Chinje, E. C., Talbot, D. C., Harris, A. L., Strafford, I. J.
Publicado 1997

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma

por Deplanque, G, Madhusudan, S, Jones, P H, Wellmann, S, Christodoulos, K, Talbot, D C, Ganesan, T S, Blann, A, Harris, A L
Publicado 2004

High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study.

por Parikh, P., Powles, R., Treleaven, J., Helenglass, G., Gore, M., Rose, M., Talbot, D., Milan, S., Smith, C., Pinkerton, R.
Publicado 1990

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.

por Ellis, P. A., Smith, I. E., Hardy, J. R., Nicolson, M. C., Talbot, D. C., Ashley, S. E., Priest, K.
Publicado 1995

Investigating Endothelial Activation and Oxidative Stress in relation to Glycaemic Control in a Multiethnic Population

por Brady, E. M., Webb, D. R., Morris, D. H., Khunti, K., Talbot, D. S. C., Sattar, N., Davies, M. J.
Publicado 2012

A phase II study of bryostatin 1 in metastatic malignant melanoma.

por Propper, D. J., Macaulay, V., O'Byrne, K. J., Braybrooke, J. P., Wilner, S. M., Ganesan, T. S., Talbot, D. C., Harris, A. L.
Publicado 1998

Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents

por Han, C, Braybrooke, J P, Deplanque, G, Taylor, M, Mackintosh, D, Kaur, K, Samouri, K, Ganesan, T S, Harris, A L, Talbot, D C
Publicado 2003

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

por Medley, L, Morel, A N, Farrugia, D, Reed, N, Hayward, N, Davies, J M, Kirichek, O, Thakker, R V, Talbot, D C
Publicado 2011

Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer.

por Koukourakis, M. I., Giatromanolaki, A., O'Byrne, K. J., Comley, M., Whitehouse, R. M., Talbot, D. C., Gatter, K. C., Harris, A. L.
Publicado 1997

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbaz...

por Propper, D J, Braybrooke, J P, Levitt, N C, O'Byrne, K, Christodoulos, K, Han, C, Talbot, D C, Ganesan, T S, Harris, A L
Publicado 2000

Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply.

por Thompson, C. H., Macaulay, V. M., O'Byrne, K. J., Kemp, G. J., Wilner, S. M., Talbot, D. C., Harris, A. L., Radda, G. K.
Publicado 1996

Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.

por O'Byrne, K. J., Koukourakis, M. I., Saunders, M. P., Salisbury, A. J., Isaacs, R., Varcoe, S., Taylor, M., Ganesan, T. S., Harris, A. L., Talbot, D. C.
Publicado 1998